By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


Company News
Ablynx (ABLYF)'s Ant-Il-6R Nanobody Partnered With AbbVie (ABBV) Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection 10/23/2014 6:36:33 AM
Ablynx (ABLYF) Announces Warrant Exercise 10/21/2014 6:17:49 AM
Ablynx (ABLYF) Establishes Sponsored Level I ADR Programme In The United States 9/5/2014 8:10:08 AM
Ablynx (ABLYF) Signs Exclusive License Agreement With Eddingpharm (Cayman) Inc. To Develop And Commercialise Its Anti-Tnfa Nanobody In Greater China 9/2/2014 7:50:35 AM
Ablynx (ABLYF) Announces Half-Year Results For 2014 8/28/2014 8:40:08 AM
Ablynx (ABLYF) Will Announce Its Half-Year Results For 2014 With Webcast 8/21/2014 7:50:21 AM
Ablynx (ABLYF) Awarded EU2.1 Million Grant To Support Development Of Novel Nanobodies® For Ocular Applications 8/13/2014 7:18:01 AM
Ablynx (ABLYF) Announces Warrant Exercise 7/18/2014 6:23:48 AM
Euronext Introduces Spotlight Options On Ablynx (ABLYF) 7/15/2014 6:10:45 AM
Ablynx (ABLYF) Release: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law") 5/20/2014 11:56:36 AM